TITLE

Nunavut government assailed over outbreak

AUTHOR(S)
Webster, Paul Christopher
PUB. DATE
April 2011
SOURCE
CMAJ: Canadian Medical Association Journal;4/19/2011, Vol. 183 Issue 7, pE379
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The article focuses on the efforts done at Nunavut to deal with respiratory syncytial virus (RSV) outbreak in the region. It says that since the government covers up disclosing data regarding the outbreak, doctor Anna Banerji recommends the use of universal antibody coverage among Inuit infants and an estimate of more than half of the 29 communities which have been inflicted by the disease. It states that RSV is the major cause of respiratory tract infections in young children and infants.
ACCESSION #
61407559

 

Related Articles

  • The Effectiveness of Ribavirin in the Treatment of RSV. Cooper, Kristina E. // Pediatric Nursing;Jan/Feb2001, Vol. 27 Issue 1, p95 

    Examines the effectiveness of ribavirin for the treatment of respiratory syncytial virus (RSV) infection in children. Cost-effectiveness of ribavirin; Criteria set by the American Academy of Pediatrics on the use of ribavirin; Benefits of ribavirin.

  • Immunoprophylaxis of respiratory syncytial virus: global experience. Simoes, Eric A. F. // Respiratory Research;2002 Supplement 1, Vol. 3, pS26 

    Respiratory syncytial virus (RSV) infects nearly all children by age 2 years, and it causes considerable illness and death in certain high-risk pediatric populations. Historically, treatment for RSV has been symptomatic, and developing a safe and effective vaccine has been a challenge....

  • A Case of Therapy of Aerosolized Ribavirin in a Leukemia Infant with RSV Infection. Hyo Jin Kwon; Myung Jin Oh; Jae Wook Lee; Nak Gyun Chung; Bin Cho; Hack Ki Kim; Jin Han Kang // Korean Journal of Pediatric Infectious Diseases;2012, Vol. 19 Issue 3, p162 

    Respiratory syncytial virus (RSV) is the major cause of lower respiratory tract infection in infants. Life-threatening RSV infection is often reported in young children and immunocompromised hosts. Since there is no report on ribavirin therapy for RSV pneumonia in pediatric cancer patients in...

  • Identificación de virus respiratorios en pacientes pediátricos con infecciones respiratorias en el Hospital Carlos Van Buren, Valparaíso. Época estival 2011-2012. Daniel Lira, M.; Ximena Collao, F.; Cindy Peña, M. // Revista ANACEM;2013, Vol. 7 Issue 2, p70 

    INTRODUCTION: Acute Respiratory infection (ARI) is a major cause of morbidity and mortality worldwide in pediatrics. The main etiological agents are respiratory syncytial virus, parainfluenza virus (PIV), influenza virus and adenovirus. Currently there are molecular diagnostic tests that have...

  • Palivizumab Injection.  // AHFS Consumer Medication Information;Oct2016, p1 

    Your child's doctor has ordered palivizumab to help prevent a serious lower respiratory tract disease called respiratory syncytial virus (RSV). The drug will be injected into a large muscle (such as the thigh) once a month for several months. It is important that your child receive this medicine...

  • Treating RSV. Villareal, Dan // RT: The Journal for Respiratory Care Practitioners;Jul2008, Vol. 21 Issue 7, p30 

    The article reports on how to treat respiratory syncytial virus (RSV), a common infection among children in the U.S. It has been recorded that there are 75,000 to 125,000 cases of RSV which occurs as an annual outbreak in U.S. that often lasts 4 to 6 months. According to the author, prevention...

  • The Significance of Transplacental Antibody Against Respiratory Syncytial Virus. Piedra, Pedro A.; Munoz, Flor M. // Journal of Infectious Diseases;Nov2014, Vol. 210 Issue 10, p1526 

    The authors comment on the effectiveness of the transplacental antibodies in fighting respiratory syncytial virus (RSV) in the U.S. The authors mention that RSV is the leading respiratory virus among young children that results to numerous mortality and morbidity. Moreover, they said that...

  • Vitamin A for treatment of acute RSV infection. Sadovsky, Richard // American Family Physician;1/1/1997, Vol. 55 Issue 1, p282 

    Summarizes a study by J.S. Bresee, et al, which appeared in the `Pediatric Infectious Disease Journal' of 1996, volume 15, that evaluated the effectiveness of high-dose Vitamin A in the treatment of acute respiratory syncytial virus (RSV) infection. Background on the study; Outline of results;...

  • Reduced-Dose Schedule of Prophylaxis Based on Local Data Provides Near-Optimal Protection Against Respiratory Syncytial Virus. Weinberger, Daniel M.; Warren, Joshua L.; Steiner, Claudia A.; Charu, Vivek; Viboud, Cécile; Pitzer, Virginia E. // Clinical Infectious Diseases;8/15/2015, Vol. 61 Issue 4, p506 

    Background. Respiratory syncytial virus (RSV) is a major cause of respiratory infections among young children and can lead to severe disease among some infants. Infants at high risk for severe RSV infection receive monthly injections of a prophylactic monoclonal antibody during the RSV season...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics